Newcastle disease virus vector-based SARS-CoV-2 vaccine candidate AVX/COVID-12 activates T cells and is recognized by antibodies from COVID-19 patients and vaccinated individuals

Supporters

Support the authors with ResearchCoin

Tip RSC

Journal

Carolina Digital Repository (University of North Carolina at Chapel Hill)

Topics

Medicine

Immunology

Pathology

Infectious Diseases

Outbreak

Show all topics

DOI

10.17615/1ggm-g948

License

CC-BY

Other Formats

PDF